Avastin helps cervical cancer patients

Share this article:

Avastin and chemotherapy added four months of survival among advanced cervical cancer patients. Medpage Today reported Friday that the study, published in the New England Journal of Medicine, showed median overall survival was 17 months with Avastin vs. 13.3 using only chemotherapy. Adding Avastin to platinum-based or nonplatinum therapy did not have a significant impact on results.

“Cervical cancer patients are often mothers with minor children. This is a major advance and clinical benefit to those patients," Memorial Sloan-Kettering Cancer Center's Carol Aghajaman told Medpage.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.